1. Home
  2. OSUR vs KPTI Comparison

OSUR vs KPTI Comparison

Compare OSUR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$2.83

Market Cap

174.3M

Sector

Health Care

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$10.02

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
KPTI
Founded
2000
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.3M
148.0M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
OSUR
KPTI
Price
$2.83
$10.02
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$3.00
$22.17
AVG Volume (30 Days)
431.5K
643.9K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,064,000.00
$146,067,000.00
Revenue This Year
N/A
$0.84
Revenue Next Year
$3.70
$46.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.57
52 Week Low
$2.08
$3.51
52 Week High
$4.22
$10.38

Technical Indicators

Market Signals
Indicator
OSUR
KPTI
Relative Strength Index (RSI) 53.32 73.08
Support Level $2.65 $5.60
Resistance Level $3.05 N/A
Average True Range (ATR) 0.12 1.01
MACD -0.01 0.34
Stochastic Oscillator 50.56 95.86

Price Performance

Historical Comparison
OSUR
KPTI

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: